ClinicalTrials.gg
Not yet recruitingNCT07946107NOBLEHEART-HCMUpdated Nov 18, 2026

BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

A Phase 3 interventional study of BHB-1893 and Placebo in Cardiomyopathy, Hypertrophic Non-Obstructive, sponsored by Braveheart Bio, Inc.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Braveheart Bio, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this trial is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy (nHCM).

02

Conditions studied

  • Cardiomyopathy, Hypertrophic Non-Obstructive

Keywords

  • Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
  • nHCM
  • HCM
  • Heart Failure
03

In context

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

This study's planned enrollment of 600 is above the median of 51 across 268 interventional studies indexed under Cardiomyopathies.

Browse Cardiomyopathies studies →

Lead sponsor

Braveheart Bio, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosed with HCM per protocol-defined criteria
  • Class II or III at screening visits
  • KCCQ-CSS that meets the protocol-specified criteria at screening visits
  • Adequate acoustic windows for echocardiography

Key Exclusion Criteria:

  • Resting systolic blood pressure (SBP) of >160 millimeters of mercury (mmHg) at screening visits
  • Resting heart rate of >100 beats per minute (bpm) at screening visits
  • Significant valvular heart disease

Additional protocol-defined inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    BHB-1893

    Participants will receive BHB-1893 twice daily.

    Drug: BHB-1893

  • Placebo comparator
    Placebo

    Participants will receive matching placebo twice daily.

    Other: Placebo

Interventions

  • DrugBHB-1893

    Tablets for oral use

  • OtherPlacebo

    Tablets for oral use

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)

    Time frame: Baseline, Week 36

  2. Change from Baseline in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise (CPET)

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Percent Change from Baseline in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Concentration

    Time frame: Baseline, Week 36

  2. Percent Change from Baseline in High-sensitivity Cardiac Troponin I (hsc-TnI) Concentration

    Time frame: Baseline, Week 36

  3. Number of Participants with >=1 Class Improvement in New York Heart Association (NYHA) Class

    Time frame: Baseline to Week 36

  4. Change from Baseline in Left Atrial Volume Index (LAVI)

    Time frame: Baseline, Week 36

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 20 phase 3 interventional studies under Cardiomyopathies, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 103. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2029
CompletionEst.
Jan 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946107
Lead sponsor
Braveheart Bio, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Study Director
Contact
clinicaltrials@braveheart.bio
(415) 707-6312
Study Director
study director · Braveheart Bio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion